Form 4: Integra LifeSciences Exec. Chairman Stuart Essig Reports Stock Transactions
SEC Form 4 Filing
Stuart Essig, Executive Chairman of Integra LifeSciences, reports the acquisition and disposition of company stock, including a contribution of 500,000 shares to a Grantor Retained Annuity Trust.
Summary
- On May 23, 2024, Stuart Essig, the Executive Chairman of the Board of Integra LifeSciences Holdings Corp, reported changes in beneficial ownership of the company's stock.
- Essig acquired 52,641 shares of common stock at a weighted average price of $28.4945.
- The purchase prices ranged from $28.31 to $28.66.
- Essig also contributed 500,000 shares of common stock to a Grantor Retained Annuity Trust (GRAT).
- Following these transactions, Essig directly owns 487,922 shares and indirectly owns 1,265,512 shares through various GRATs and a trust.
Sentiment
Score: 5
Explanation: Neutral sentiment as the document simply reports stock transactions without expressing any positive or negative outlook.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and actions regarding their company's stock.
Stakeholder Impact
- The transactions may influence investor perception of the company's stock.
Key Dates
| Date | Description |
|---|---|
| 05/23/2024 | Date of stock acquisition and contribution to GRAT |
| 05/24/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.